MR spectroscopic imaging predicts early response to anti-angiogenic therapy in recurrent glioblastoma.

Pratik TalatiMohamed El-AbtahDaniel KimJorg DietrichMelanie FuMichael WenkeJulian HeSharif N NatheirMark VangelOtto RapalinoAnna VaynrubIsabel Arrillaga-RomanyDeborah A ForstYi-Fen YenOvidiu AndronesiJayashree Kalpathy-CramerBruce RosenTracy T BatchelorR Gilberto GonzalezElizabeth R GerstnerEva-Maria Ratai

Published in: Neuro-oncology advances (2021)

Changes in metabolic levels of tumoral NAA/Cho and Lac/NAA can serve as early biomarkers for predicting treatment failure to anti-angiogenic therapy as soon as 1 day after bevacizumab-based therapy. The addition of MRS to conventional MR methods can provide better insight into how anti-angiogenic therapy affects tumor microenvironment and predict patient outcomes.

Keyphrases

magnetic resonance
high resolution
magnetic resonance imaging
stem cells
mass spectrometry
bone marrow
molecular dynamics simulations
smoking cessation
fluorescence imaging